Protagonist Therapeutics Achieves Analyst Price Target
Current Stock Performance: Protagonist Therapeutics Inc (PTGX) shares have surpassed the average analyst 12-month target price of $89.77, trading at $89.86/share, prompting potential analyst reactions regarding valuation adjustments.
Analyst Target Range: There are 13 analyst targets for PTGX, with a wide range from a low of $65.00 to a high of $112.00, indicating varying opinions on the stock's future performance.
Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a path to higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.
Analyst Rating System: The article references an average rating system for analysts covering PTGX, where ratings range from 1 (Strong Buy) to 5 (Strong Sell), reflecting the collective sentiment towards the stock.
Get Free Real-Time Notifications for Any Stock
Analyst Views on PTGX
About PTGX
About the author
Takeda Submits NDA for Rusfertide, Potential $400M Opt-Out Payment
- NDA Submission: Takeda Pharmaceutical and Protagonist Therapeutics announced the submission of a New Drug Application for rusfertide targeting polycythemia vera, supported by positive 32-week primary analysis and 52-week results from the Phase 3 VERIFY study, which could open new revenue streams for the company.
- Triggering Agreement Terms: The NDA submission initiates a 120-day decision period, during which Protagonist can opt-out within a subsequent 90-day window, potentially securing up to $400 million in opt-out payments, thereby enhancing the company's cash flow.
- Milestone Payments and Royalties: Should Protagonist opt-out, it would be eligible for additional milestone payments and tiered royalty rates of 14-29% on worldwide net sales, significantly boosting its future revenue potential and financial stability.
- Market Reaction: Following the announcement, Takeda's stock traded down 0.13% on the NYSE, while Protagonist's stock rose 0.37% on Nasdaq, reflecting a cautiously optimistic market sentiment regarding the new drug application.
S&P 500 Futures Rise in Pre-Market Trading; Blue Hat Interactive and Sunoco Take the Lead
Market Opening: U.S. stock markets are set to open in two hours.
Blue Hat Interactive Performance: Blue Hat Interactive Entertainment Technology (BHAT) saw a 9.5% increase in pre-market trading.
Sunoco L.P. Performance: Sunoco L.P. (SUN) experienced a 7.4% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors ahead of the market opening.
